BISPESIFIK IL-17A DAN IL-17F (IL-17A/F) SEBAGAI INOVASI TERAPI TERBARU BAGI PARA PENDERITA PSORIASIS: SEBUAH TELAAH PUSTAKA SISTEMATIS
Abstrak
Introduction: Psoriasis is a chronic inflammatory skin disease characterized with redness, scaling, induration, itchiness, and thickness of skin that worsen quality of life, particularly in moderate to severe psoriatic patients. Although the emergence of biologics has provided revolutionary therapy in the management of moderate to severe psoriasis, significant number of patient has shown ineffectiveness. Recent studies suggest the use of bispecific antibodies as an effective and efficient alternatives . This review aims to evaluate the effectiveness and adverse side effects of bispecific IL-17A/F in various clinical studies. Discussion: This paper yields results that ~100% and >80% of patients treated with bispecific IL-17A/F is able to achieve PASI75 and PASI90, respectively, by week 12 in phase I and II studies. Moreover, bispecific IL-17A/F is able to significantly reduce inflammatory response in psoriatic skin biopsies. Only mild treatment-related adverse events is reported and no immunogenicity is detected. Conclusion: Bispecific IL-17A/F provides effective therapy with minimal adverse side effects within a short amount of time. Further study is needed to compare its effectiveness against other biologics.
Keywords: bimekizumab, biologics, bispecific IL17A/F, M1095, psoriasis, systematic review
##plugins.generic.usageStats.downloads##
##plugins.generic.usageStats.noStats##
Referensi
DAFTAR PUSTAKA
1. NCDs | Psoriasis. World Health Organization; 2018. [Diakses 2019 Jun 9]. Dari: https://www.who.int/ncds/management/psoriasis/en/
2. Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20. doi:10.1590/abd1806-4841.20153038
3. Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297.
4. Global report on psoriasis. World Health Organization. [Diakses 2019 Jun 9]. Dari: http://www.who.int/iris/handle/10665/204417
5. Owczarczyk-Saczonek A, Placek W. Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders. Int J Dermatol. 2017;56(3):260-268.
6. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653.
7. Szepietowski JC, Reich A. Pruritus in psoriasis: An update. Eur J Pain. 2016;20(1):41-6.
8. Warren RB, Mrowietz U, Kiedrowski RV, Niesmann J, Wilsmann-Theis D, Ghoreschi K, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017;389(10068):528–37.
9. Maul J-T, Djamei V, Kolios AG, Meier B, Czernielewski J, Jungo P, et al. Efficacy and survival of systemic psoriasis treatments: an analysis of the swiss registry SDNTT. Dermatology. 2016;232(6):640–7.
10. Manalo IF, Gilbert KE, Wu JJ. Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100. J Drugs Dermatol. 2015;14(10):1086-8.
11. Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, et al. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials. International Immunopharmacology. 2018;62:46–58.
12. Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. Journal of Dermatological Treatment. 2018;29(6):569–78.
13. Jabbar-Lopez ZK, Yiu ZZN, Ward V, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017;137(8):1646–1654. doi:10.1016/j.jid.2017.04.009
14. Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12(12):CD011535.
15. Vide J, Magina S. Moderate to severe psoriasis treatment challenges through the era of biological drugs. An Bras Dermatol. 2017;92(5):668-674.
16. Svedbom A, Dalen J, Mamolo C, Cappelleri JC, Petersson IF, Stahle M. Treatment patterns with topicals, traditional systemics and biologics in psoriasis – a Swedish database analysis. JEADV. 2015;29(2):215-223.
17. Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. J Dermatol. 2019;46(5):389-398.
18. Armstrong AW, Foster SA, Comer BS, Lin CY, Malatestinic W, Burge R, et al. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. BMC Dermatol. 2018;18(1):4.
19. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131:677–687.
20. Silacci M, Lembke W, Woods R, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs. 2016;8:141–149.
21. Mease PJ, Genovese MC, Weinblatt ME, et al. Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17a-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate. Arthritis Rheumatol. 2018;70(11):1778–1789.
22. Maroof A, Okoye R, Smallie T, Baeten D, Archer S, Simpson C, et al. Bimekizumab dual inhibition of IL-17A and IL-17F provides evidence of IL-17F contribution to chronic inflammation in disease-relevant cells. Arthritis Rheumatol. 2017; 69 (suppl 10).
23. Maroof A, Smallie T, Archer S, Simpson CL, Griffiths M, et al. Dual IL-17A and IL-17F inhibition with bimekizumab provides evidence for IL-17F contribution to immune-mediated inflammatory skin response. J Invest Dermatol. 2017;137:S120.
24. Maroof A, Baeten D, Archer S, Griffiths M, Shaw S. IL-17F contributes to human chronic inflammation in synovial tissue: preclinical evidence with dual IL-17A and IL-17F inhibition with bimekizumab in psoriatic arthritis. Ann Rheum Dis. 2017;76:A13-A.
25. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–532.
26. Vanheusden K, Detalle L, Hemeryck A, et al. Pre-clinical proof-of-concept of ALX-0761, a nanobody neutralising both IL-17A and IL-17F in a cynomolgus monkey collagen induced arthritis model. Poster n. 1287, presented at the Annual Meeting of the American College of Rheumatology (ACR); 2013 Oct 26–30; San Diego, CA.
27. Natsis NE, Gottlieb AB. Bimekizumab for the treatment of psoriatic disease. Expert Opinion on Biological Therapy. 2018;18(12):1193-1197.
28. Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83:991–1001.
29. Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79:277–286.e10.
30. Svecova D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger JG. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin-17A/F Nanobody, in moderate-to severe psoriasis. J Am Acad Dermatol. 2019;S0190-9622(19):30500–6.
1. NCDs | Psoriasis. World Health Organization; 2018. [Diakses 2019 Jun 9]. Dari: https://www.who.int/ncds/management/psoriasis/en/
2. Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20. doi:10.1590/abd1806-4841.20153038
3. Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297.
4. Global report on psoriasis. World Health Organization. [Diakses 2019 Jun 9]. Dari: http://www.who.int/iris/handle/10665/204417
5. Owczarczyk-Saczonek A, Placek W. Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders. Int J Dermatol. 2017;56(3):260-268.
6. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653.
7. Szepietowski JC, Reich A. Pruritus in psoriasis: An update. Eur J Pain. 2016;20(1):41-6.
8. Warren RB, Mrowietz U, Kiedrowski RV, Niesmann J, Wilsmann-Theis D, Ghoreschi K, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017;389(10068):528–37.
9. Maul J-T, Djamei V, Kolios AG, Meier B, Czernielewski J, Jungo P, et al. Efficacy and survival of systemic psoriasis treatments: an analysis of the swiss registry SDNTT. Dermatology. 2016;232(6):640–7.
10. Manalo IF, Gilbert KE, Wu JJ. Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100. J Drugs Dermatol. 2015;14(10):1086-8.
11. Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, et al. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials. International Immunopharmacology. 2018;62:46–58.
12. Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. Journal of Dermatological Treatment. 2018;29(6):569–78.
13. Jabbar-Lopez ZK, Yiu ZZN, Ward V, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017;137(8):1646–1654. doi:10.1016/j.jid.2017.04.009
14. Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12(12):CD011535.
15. Vide J, Magina S. Moderate to severe psoriasis treatment challenges through the era of biological drugs. An Bras Dermatol. 2017;92(5):668-674.
16. Svedbom A, Dalen J, Mamolo C, Cappelleri JC, Petersson IF, Stahle M. Treatment patterns with topicals, traditional systemics and biologics in psoriasis – a Swedish database analysis. JEADV. 2015;29(2):215-223.
17. Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. J Dermatol. 2019;46(5):389-398.
18. Armstrong AW, Foster SA, Comer BS, Lin CY, Malatestinic W, Burge R, et al. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. BMC Dermatol. 2018;18(1):4.
19. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131:677–687.
20. Silacci M, Lembke W, Woods R, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs. 2016;8:141–149.
21. Mease PJ, Genovese MC, Weinblatt ME, et al. Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17a-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate. Arthritis Rheumatol. 2018;70(11):1778–1789.
22. Maroof A, Okoye R, Smallie T, Baeten D, Archer S, Simpson C, et al. Bimekizumab dual inhibition of IL-17A and IL-17F provides evidence of IL-17F contribution to chronic inflammation in disease-relevant cells. Arthritis Rheumatol. 2017; 69 (suppl 10).
23. Maroof A, Smallie T, Archer S, Simpson CL, Griffiths M, et al. Dual IL-17A and IL-17F inhibition with bimekizumab provides evidence for IL-17F contribution to immune-mediated inflammatory skin response. J Invest Dermatol. 2017;137:S120.
24. Maroof A, Baeten D, Archer S, Griffiths M, Shaw S. IL-17F contributes to human chronic inflammation in synovial tissue: preclinical evidence with dual IL-17A and IL-17F inhibition with bimekizumab in psoriatic arthritis. Ann Rheum Dis. 2017;76:A13-A.
25. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–532.
26. Vanheusden K, Detalle L, Hemeryck A, et al. Pre-clinical proof-of-concept of ALX-0761, a nanobody neutralising both IL-17A and IL-17F in a cynomolgus monkey collagen induced arthritis model. Poster n. 1287, presented at the Annual Meeting of the American College of Rheumatology (ACR); 2013 Oct 26–30; San Diego, CA.
27. Natsis NE, Gottlieb AB. Bimekizumab for the treatment of psoriatic disease. Expert Opinion on Biological Therapy. 2018;18(12):1193-1197.
28. Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83:991–1001.
29. Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79:277–286.e10.
30. Svecova D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger JG. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin-17A/F Nanobody, in moderate-to severe psoriasis. J Am Acad Dermatol. 2019;S0190-9622(19):30500–6.
Diterbitkan
2020-08-01
##submission.howToCite##
KUATAMA, Rexel; RUBY, Rivaldi; MANGKULIGUNA, Ghea.
BISPESIFIK IL-17A DAN IL-17F (IL-17A/F) SEBAGAI INOVASI TERAPI TERBARU BAGI PARA PENDERITA PSORIASIS: SEBUAH TELAAH PUSTAKA SISTEMATIS.
Essence of Scientific Medical Journal, [S.l.], v. 18, n. 1, p. 32-40, aug. 2020.
ISSN 2655-6472.
Tersedia pada: <http://103.29.196.112/index.php/essential/article/view/53778>. Tanggal Akses: 04 mar. 2026
Bagian
Artikel Tinjauan Pustaka
